Literature DB >> 20451293

Disseminated superficial actinic porokeratosis co-existing with linear and verrucous porokeratosis in an elderly woman: Update on the genetics and clinical expression of porokeratosis.

Jenny Murase1, Anita C Gilliam.   

Abstract

Disseminated superficial actinic porokeratosis (DSAP) is the most common form of porokeratosis, occurring mainly in women on the extremities as atrophic patches rimmed by a ridge of keratin (the cornoid lamella that is diagnostic of porokeratosis histologically and is thought to be a clonal keratinocyte proliferation). DSAP can sometimes coexist with other forms of porokeratosis (Mibelli, linear porokeratosis, porokeratosis palmaris et plantaris disseminata, and punctate porokeratosis). Rare variants of linear porokeratosis are the hyperkeratotic and verrucous forms which usually occur on the buttocks or perianal area. We present clinical and histopathologic findings from biopsy specimens of a 73-year-old woman with DSAP on the distal extremities, linear/segmental porokeratosis on thighs, and verrucous porokeratosis on buttocks and mons pubis. The verrucous lesions had been present for 30+ years, the DSAP and linear lesions for 10+ years. Biopsy specimens from distal extremity showed classic features of DSAP with infrequent cornoid lamellae separated by atrophic epidermis. Biopsy specimens from the mons pubis and thigh showed epidermal hyperplasia with multiple, almost contiguous, broad cornoid lamellae. Coexisting variants of porokeratosis are rare and our conclusions are drawn from a few cases in the literature. The rare variants of porokeratosis are of interest because the clinical morphology correlates with the histopathology.
Copyright © 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20451293     DOI: 10.1016/j.jaad.2009.07.038

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  9 in total

1.  [77-year-old female with persisting erythematous and scaly plaques on the extremities and upper trunk : Preparation for the medical specialist examination: Part 20].

Authors:  Susanne Darr-Foit; Peter Elsner
Journal:  Hautarzt       Date:  2018-11       Impact factor: 0.751

2.  [Centrifugal plaques with central atrophy and peripheral scale on the scalp].

Authors:  P Nenoff; T Arnold; H Nenning; W Hindermann
Journal:  Hautarzt       Date:  2011-07       Impact factor: 0.751

3.  Mixed porokeratosis with a novel mevalonate kinase gene mutation: A case report.

Authors:  Hong-Jun Xu; Guang-Dong Wen
Journal:  World J Clin Cases       Date:  2022-05-16       Impact factor: 1.534

4.  Porokeratosis and malignancy: Incidental or causal association?

Authors:  Najeeba Riyaz
Journal:  Indian Dermatol Online J       Date:  2015 Nov-Dec

5.  Disseminated superficial actinic porokeratosis on the face treated with imiquimod 5% cream.

Authors:  Hassan Riad; Khaled Mansour; Hussein Al Sada; Samya Abu Shaika; Hamda Al Ansari; Haya Al Mohannadi
Journal:  Case Rep Dermatol       Date:  2013-10-09

6.  Generalized linear porokeratosis.

Authors:  Claudio Escanilla-Figueroa; Isabel Jimeno-Ortega; Héctor Fuenzalida-Wong; Francisco Chávez-Rojas
Journal:  An Bras Dermatol       Date:  2018-06       Impact factor: 1.896

7.  Disseminated Superficial Actinic Porokeratosis (DSAP): A Case Report Highlighting the Clinical, Dermatoscopic, and Pathology Features of the Condition.

Authors:  Muhammad Umer Waqar; Philip R Cohen; Simona Fratila
Journal:  Cureus       Date:  2022-07-16

8.  Late-onset disseminated superficial actinic porokeratosis in an elderly woman.

Authors:  Aida Khaled; Mouna Kourda; Fadoua Abdelmoula; Lilia M'ssedi; Mohamed Nejib Tougourti; Mohamed Ridha Kamoun
Journal:  Dermatol Ther (Heidelb)       Date:  2011-05-20

9.  Disseminated Superficial Actinic Porokeratosis in a Patient with Psoriasis, after Long-Term Narrowband Ultraviolet B Phototherapy.

Authors:  Chang Yoon Sim; Ji Yeoun Shin; Sung Yul Lee; Young Lip Park
Journal:  Ann Dermatol       Date:  2018-02-21       Impact factor: 1.444

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.